17 results on '"Kronbichler, Andreas"'
Search Results
2. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis.
- Author
-
Kronbichler, Andreas, Leierer, Johannes, Shin, Jae Il, Merkel, Peter A., Spiera, Robert, Seo, Philip, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G. M., St.Clair, E. William, Brunetta, Paul, Fervenza, Fernando C., Geetha, Duvuru, Keogh, Karina A., Monach, Paul A., Ytterberg, Steven R., Mayer, Gert, Specks, Ulrich, and Stone, John H.
- Subjects
- *
AUTOIMMUNE disease diagnosis , *HEMORRHAGE complications , *THROMBOEMBOLISM risk factors , *RITUXIMAB , *ERYTHROCYTES , *AGE distribution , *AUTOIMMUNE diseases , *CONFIDENCE intervals , *HEART , *HEMATURIA , *LUNG diseases , *MULTIVARIATE analysis , *PROTEOLYTIC enzymes , *RISK assessment , *SEX distribution , *STATISTICS , *URINALYSIS , *VASCULITIS , *VEINS , *TREATMENT effectiveness , *DISEASE duration , *ODDS ratio , *ANTINEUTROPHIL cytoplasmic antibodies , *DISEASE complications - Abstract
Objective: To assess the frequency of venous thromboembolism (VTE) events in the Rituximab in Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis (RAVE) trial and identify novel potential risk factors. Methods: VTE events in 197 patients enrolled in the RAVE trial were analyzed. Baseline demographic and clinical characteristics were recorded, and univariate and multivariate analyses were performed to identify factors associated with VTE in ANCA‐associated vasculitis (AAV). Results: VTE occurred in 16 patients (8.1%) with an overall average time to event of 1.5 months (range 1.0–2.75). In univariate analyses with calculation of hazard ratios (HRs) and 95% confidence intervals (95% CIs), heart involvement (HR 17.408 [95% CI 2.247–134.842]; P = 0.006), positive proteinase 3 (PR3)–ANCA (HR 7.731 [95% CI 1.021–58.545]; P = 0.048), pulmonary hemorrhage (HR 3.889 [95% CI 1.448–10.448]; P = 0.008), and the presence of red blood cell casts (HR 15.617 [95% CI 3.491–69.854]; P < 0.001) were associated with the onset of VTE. In multivariate models adjusted for age and sex, the significant associations between VTE events and heart involvement (HR 21.836 [95% CI 2.566–185.805]; P = 0.005), PR3‐ANCA (HR 9.12 [95% CI 1.158–71.839]; P = 0.036), pulmonary hemorrhage (HR 3.91 [95% CI 1.453–10.522]; P = 0.007), and urinary red blood cell casts (HR 16.455 [95% CI 3.607–75.075]; P < 0.001) remained. Conclusion: Patients diagnosed as having AAV with pulmonary hemorrhage, positive PR3‐ANCA, heart involvement, and the presence of red blood cell casts are at an increased risk to develop VTE. Further studies are needed to confirm and expand these findings and to explore the mechanisms of hypercoagulability in these patients with the aim of informing potential targets for therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. ANCA associated vasculitis: The journey to complement-targeted therapies.
- Author
-
Quintana, Luis F., Kronbichler, Andreas, Blasco, Miquel, Zhao, Ming-hui, and Jayne, David
- Subjects
- *
RITUXIMAB , *CHRONIC kidney failure , *COMPLEMENT activation , *URINALYSIS , *THERAPEUTICS - Abstract
• End stage renal disease by ANCA vasculitis affects 40% of the patients. • Major hurdles are the complex balance between treatment toxicity and recurrence. • New data indicate that C5 and C5aR are therapeutic targets in ANCA renal vasculitis. • The way is open for clinical use of this complement target therapy in the near future. ANCA associated vasculitis is a serious, very often recurrent disease that despite the current standard treatment with high-dose glucocorticoids and either cyclophosphamide or rituximab, patients have a nine-fold increased mortality risk in the first year compared with healthy controls, attributed to infections, vasculitis activity, and renal disease. During the last few years, novel findings have suggested that activation of the complement system, in particular the alternative complement system, has a significant role in ANCA associated vasculitis pathogenesis. Detection of several components of this system in the circulation and urine reflects disease activity, and thus may be useful for clinical prognosis and to set up personalised treatments. In fact, some components of the complement system, such as C5a, might be potential targets for therapy. In this Review an update on clinical evidence for the role of complement activation in AAV is provided and subsequently we discuss potential therapeutic strategies that target complement components and open the way for clinical use of this target therapy in the near future. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Rituximab in minimal change disease and focal segmental glomerulosclerosis.
- Author
-
Kronbichler, Andreas, Gauckler, Philipp, and Bruchfeld, Annette
- Subjects
- *
FOCAL segmental glomerulosclerosis , *RITUXIMAB , *REGULATORY T cells - Published
- 2021
- Full Text
- View/download PDF
5. Refractory lupus nephritis: When, why and how to treat.
- Author
-
Kronbichler, Andreas, Brezina, Biljana, Gauckler, Philipp, Quintana, Luis F., and Jayne, David R.W.
- Subjects
- *
LUPUS nephritis , *CHRONIC kidney failure , *STEM cell transplantation , *THERAPEUTICS - Abstract
Refractory lupus nephritis indicates an inadequate response to lupus nephritis therapy. It implies persisting or worsening disease activity despite therapy, but the definition is complicated by the parameters of response, proteinuria and renal function, that do not discriminate clearly between activity and irreversible damage. Understanding the causes of refractory disease and developing treatment strategies is important because these patients are more likely to develop poor outcomes, especially end stage renal disease. This review explores current concepts and definitions of refractory disease and summarises treatment approaches that have been used in observational cohort studies and case series. We highlight the importance of optimising adherence to the prescribed immunosuppressive and supportive measures and avoidance of diagnostic delay. Treatment options include higher dose glucocorticoid, switching between cyclophosphamide and mycophenolate acid derivates, or addition of rituximab, the latter potentially in combination with belimumab. Less evidence supports extracorporeal treatment (plasma exchange or immunoadsorption), calcineurin inhibitors (cyclosporine A or tacrolimus), intravenous immunoglobulin and stem cell transplantation. Improvements in understanding what refractory disease is and how definitions can be integrated into treatment pathways has the potential to enhance lupus nephritis outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Orbital masses in ANCA-associated vasculitis: an unsolved challenge?
- Author
-
Berti, Alvise and Kronbichler, Andreas
- Subjects
- *
AUTOIMMUNE disease diagnosis , *IMMUNOSUPPRESSIVE agents , *RITUXIMAB , *CYCLOPHOSPHAMIDE , *ADRENOCORTICAL hormones , *AUTOIMMUNE diseases , *BLINDNESS , *DIAGNOSIS , *ORBITAL diseases , *MEDICAL errors , *SERIAL publications , *VASCULITIS , *TREATMENT effectiveness , *SYMPTOMS , *THERAPEUTICS - Abstract
The authors discuss a report on the description of clinical features and disease course of orbital masses in ANCA-associated vasculitis (AAV). Topics discussed include factors predicting the onset of orbital masses in the context of AAV, a diagnostic pathway to minimize diagnostic delay and improve the management of subset of patients, and comparison of first-line treatment of a cyclophosphamide- to a rituximab-based regimen.
- Published
- 2019
- Full Text
- View/download PDF
7. Rituximab for immunologic renal disease: What the nephrologist needs to know.
- Author
-
Kronbichler, Andreas, Windpessl, Martin, Pieringer, Herwig, and Jayne, David R.W.
- Subjects
- *
RITUXIMAB , *KIDNEY disease treatments , *NEPHROLOGISTS , *MEDICATION safety , *DRUG side effects - Abstract
Rituximab (RTX), a chimeric, monoclonal anti-CD20 antibody, is increasingly used in immune-mediated renal diseases. While licensed in the induction treatment of ANCA-associated vasculitis, it represents one of the most commonly prescribed off-label drugs. Much of the information regarding its safety has been drawn from experience in hematology and rheumatology. Ample evidence illustrates the safety of RTX, however, rare but serious adverse events have emerged that include progressive multifocal leucoencephalopathy and hepatitis B reactivation. Moderate to severe hypogammaglobulinemia and late-onset neutropenia following RTX therapy confer an increased infectious risk and factors predicting these side effects (i.e. a genetic basis) need to be identified. Nephrologists initiating RTX need to bear in mind that long-term risks and optimal dosing for many renal indications remain unclear. Special considerations must be given when RTX is used in women of childbearing age. We summarize practical aspects concerning the use of RTX. This review will provide nephrologists with information to guide their use of RTX alerting them to safety risks and the need for patient counselling. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
- Author
-
Kronbichler, Andreas and Jayne, David R. W.
- Subjects
- *
VASCULITIS , *NEUTROPHILS , *CYTOPLASM , *IMMUNOGLOBULINS , *VASCULITIS treatment , *RITUXIMAB , *PATIENTS - Abstract
Rituximab has enriched our armamentarium in the treatment of anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis. Two randomised controlled trials have shown that rituximab is non-inferior compared with cyclophosphamide followed by azathioprine for the induction of remission. The newly diagnosed patients in the Rituximab in ANCA-Associated Vasculitis (RAVE) and Rituximab Versus Cyclophosphamide in ANCA-Associated Vasculitis (RITUXVAS) trials had a numerically higher response rate in the cyclophosphamide/azathioprine arm, and the number of such patients treated with rituximab numbered <90.We are arguing that in newly diagnosed patients, the evidence for rituximab requires further confirmation and the length of experience with a cyclophosphamide-based induction therapy supports it continuing as the preferred first choice for induction. Also, there is an absence of information regarding rituximab as 'sole' remission induction along with steroids in patients with advanced renal presentations or lung haemorrhage. Reported side effects were similar in both trials; however, the number of participants with at least one serious adverse event following rituximab induction treatment was numerically higher in the RAVE trial. In addition, hypogammaglobulinaemia with the need of substitution in some cases and late-onset neutropaenia are complications not seen with cyclophosphamide. Over the longer term it is unclear what relapse prevention strategy should be employed after rituximab, and there was a trend to a higher relapse risk after rituximab in the RITUXVAS trial at 2 years. Further health economic studies are required to understand all the costs associated with rituximab. In the context of concomitant underlying infectious complications, in terms of fertility concerns, especially in young patients, and when malignancy is underlying we would recommend the use of rituximab as first-line therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Rituximab in Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis.
- Author
-
Kronbichler, andreas and Bruchfeld, annette
- Subjects
- *
RITUXIMAB , *IMMUNOSUPPRESSIVE agents , *FOCAL segmental glomerulosclerosis , *KIDNEY glomerulus diseases , *KIDNEY diseases , *NEPHROTIC syndrome treatment , *THERAPEUTICS - Abstract
Treatment of nephrotic syndrome due to minimal change disease and focal segmental glomerulosclerosis remains a challenge since steroid dependence, steroid resistance and a relapsing disease course exhibits a high cumulative steroid dosage. The necessity of using alternative steroid-sparing immunosuppressive agents with potential toxic side effects also restricts their long-term use. Rituximab, a monoclonal antibody targeting CD20, has been increasingly used in the therapy of difficult-to-treat nephrotic syndrome. A clinical response has been shown for patients with steroid-dependent or frequently relapsing nephrotic syndrome, whereas the benefit seems to be limited in steroid-resistant patients, especially those with underlying focal segmental glomerulosclerosis. No potentially life-threatening adverse events have been observed in the treatment of adult minimal change disease and focal segmental glomerulosclerosis following rituximab administration. Since most reports are retrospective and evidence of efficacy is derived from small case series, more prospective trials in a controlled, randomized manner are highly desirable to delineate the use of rituximab or other B cell-depleting agents in steroid-dependent, frequently relapsing or steroid-resistant patients. © 2014 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?
- Author
-
Kronbichler, Andreas and Mayer, Gert
- Subjects
- *
NEPHROTIC syndrome , *MONOCLONAL antibodies , *ELECTROMAGNETIC waves , *SPECTRUM analysis , *CHANGE blindness - Abstract
Implication for health policy/practice/research/medical education: Reports on patients with steroid-dependent nephrotic syndrome and underlying minimal change disease or focal segmental glomerulosclerosis have shown promising results. There is a strong need for more trials conducted in a prospective, controlled manner to clearly recommend rituximab therapy in this indication on a regular basis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature.
- Author
-
Nakagomi, Daiki, Kronbichler, Andreas, Witte, Torsten, Mohammad, Aladdin J, and Jayne, David R W
- Subjects
- *
RITUXIMAB , *INFLIXIMAB , *TOCILIZUMAB , *INTERLEUKINS , *TUMOR necrosis factors , *DISEASE management , *TREATMENT effectiveness , *DISEASE remission , *PATIENTS' attitudes , *TAKAYASU arteritis , *CHEMICAL inhibitors , *DIAGNOSIS , *THERAPEUTICS - Published
- 2018
- Full Text
- View/download PDF
12. Nephrotic Syndrome: Genetics, Mechanism, and Therapies.
- Author
-
Shin, Jae Il, Kronbichler, Andreas, Oh, Jun, and Meijers, Björn
- Subjects
- *
RITUXIMAB , *GENETIC polymorphisms , *NEPHROTIC syndrome , *SERIAL publications , *FOCAL segmental glomerulosclerosis - Published
- 2018
- Full Text
- View/download PDF
13. Opponent's comments.
- Author
-
Kronbichler, Andreas and Jayne, David R. W.
- Subjects
- *
LUNG disease treatment , *CRITICAL care medicine , *CYCLOPHOSPHAMIDE , *COMBINATION drug therapy , *RITUXIMAB ,THERAPEUTIC use of glucocorticoids - Published
- 2015
- Full Text
- View/download PDF
14. Rituximab for patients with nephrotic syndrome.
- Author
-
Jae Il Shin and Kronbichler, Andreas
- Subjects
- *
RITUXIMAB , *NEPHROTIC syndrome - Abstract
A letter to the editor is presented in response to a trial by Kazumoto lijima and colleagues on the effectiveness of rituximab for patients with nephrotic syndrome.
- Published
- 2015
- Full Text
- View/download PDF
15. Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.
- Author
-
Stevens, Kate I, Frangou, Eleni, Shin, Jae I l, Anders, Hans-Joachim, Bruchfeld, Annette, Schönermarck, Ulf, Hauser, Thomas, Westman, Kerstin, Fernandez-Juarez, Gema M, Floege, Jürgen, Goumenos, Dimitrios, Turkmen, Kultigin, Kooten, Cees van, McAdoo, Stephen P, Tesar, Vladimir, Segelmark, Mårten, Geetha, Duvuru, Jayne, David R W, Kronbichler, Andreas, and (EUVAS), Immunonephrology Working Group (IWG) of the European Renal Association (ERA) and the European Vasculitis Society
- Subjects
- *
COVID-19 , *COVID-19 vaccines , *VACCINE effectiveness , *BOOSTER vaccines , *HUMORAL immunity , *KIDNEY diseases - Abstract
Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or comorbidities and complications caused by the underlying disease. Humoral vaccine response, measured by the presence of antibodies, is impaired or absent in patients receiving rituximab, mycophenolate mofetil (MMF), higher doses of glucocorticoids and likely other immunosuppressants, such as cyclophosphamide. The timing between the use of these agents and administration of vaccines is associated with the level of immune response: with rituximab, vaccine response can only be expected once B cells start to recover and patients with transient discontinuation of MMF mount a humoral response more frequently. The emergence of new COVID-19 variants and waning of vaccine-induced immunity highlight the value of a booster dose and the need to develop mutant-proof vaccines. COVID-19 vaccines are safe, exhibiting a very low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. management of membranous nephropathy—an update.
- Author
-
Caravaca-Fontán, Fernando, Fernández-Juárez, Gema M, Floege, Jürgen, Goumenos, Dimitrios, Kronbichler, Andreas, Turkmen, Kultigin, Kooten, Cees van, Frangou, Eleni, Stevens, Kate I, Segelmark, Mårten, Tesar, Vladimir, Anders, Hans-Joachim, and Bruchfeld, Annette
- Subjects
- *
KIDNEY diseases , *KIDNEY glomerulus diseases , *THERAPEUTICS , *DISEASE management , *CLINICAL trials - Abstract
In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
- Author
-
Kim, Jong Yeob, Lee, Keum Hwa, Eisenhut, Michael, van der Vliet, Hans J., Kronbichler, Andreas, Jeong, Gwang Hun, Shin, Jae Il, and Gamerith, Gabriele
- Subjects
- *
THERAPEUTIC use of interferons , *THERAPEUTIC use of monoclonal antibodies , *RITUXIMAB , *ANTINEOPLASTIC agents , *CANCER chemotherapy , *CHRONIC lymphocytic leukemia , *CONFIDENCE intervals , *IMMUNOTHERAPY , *LUNG cancer , *LYMPHOMAS , *MEDLINE , *MELANOMA , *METASTASIS , *ONLINE information services , *SURVIVAL , *TUMORS , *SYSTEMATIC reviews , *TREATMENT effectiveness , *DESCRIPTIVE statistics - Abstract
We conducted a systematic review for evidence of the clinical efficacy of cancer immunotherapies. We searched PubMed from inception to 14 February 2018 for meta-analyses of randomized controlled trials (RCTs) of cancer immunotherapies. Re-analyses were performed to estimate the summary effect size under random-effects, the 95% confidence interval (CI), heterogeneity, and the 95% prediction interval, and we determined the strength of the evidence. We examined publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy for treating chronic lymphocytic leukemia and B-cell non-Hodgkin's lymphoma, adoptive cell immunotherapy for NSCLC, and the combination of interferon α and chemotherapy for metastatic melanoma. A further meta-analysis of 16 RCTs showed that anti-PD-1/PD-L1 mAb therapy had a benefit in patients with solid tumors (overall survival; hazard ratio = 0.73, 95% CI: 0.68–0.79; p < 0.001), supported by convincing evidence. In the future, rigorous approaches are needed when interpreting meta-analyses to gain better insight into the true efficacy of cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.